{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:57Z","timestamp":1793106837564,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02645-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:01:42Z","timestamp":1775606502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study"],"prefix":"10.1038","volume":"11","author":[{"given":"Shuang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin KW","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-0111","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-4162","authenticated-orcid":false,"given":"Qin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena Perez","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Rafael Martins de","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Shreenivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago Bueno de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo Baston","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Vasconcelos","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-5147","authenticated-orcid":false,"given":"Zhongmin Maxwell","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-3311","authenticated-orcid":false,"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-808X","authenticated-orcid":false,"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2645_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3892\/ijo.2023.5545","volume":"63","author":"H Huang","year":"2023","unstructured":"Huang, H. et al. Immunotherapy for nasopharyngeal carcinoma: current status and prospects (Review). Int. J. Oncol. 63, 97 (2023).","journal-title":"Int. J. Oncol."},{"key":"2645_CR2","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.31557\/APJCP.2020.21.11.3291","volume":"21","author":"I Argirion","year":"2020","unstructured":"Argirion, I. et al. Subtype specific nasopharyngeal carcinoma incidence and survival trends: differences between endemic and nonendemic populations. Asian Pac. J. Cancer Prev. 21, 3291\u20133299 (2020).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2645_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2645_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10555-024-10176-9","volume":"43","author":"ZY Su","year":"2024","unstructured":"Su, Z. Y., Siak, P. Y., Lwin, Y. Y. & Cheah, S. C. Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metast. Rev. 43, 919\u2013939 (2024).","journal-title":"Cancer Metast. Rev."},{"key":"2645_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5582\/ddt.2017.01030","volume":"11","author":"N Roy Chattopadhyay","year":"2017","unstructured":"Roy Chattopadhyay, N., Das, P., Chatterjee, K. & Choudhuri, T. Higher incidence of nasopharyngeal carcinoma in some regions in the world confers for interplay between genetic factors and external stimuli. Drug Discov. Ther. 11, 170\u2013180 (2017).","journal-title":"Drug Discov. Ther."},{"key":"2645_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3389\/fonc.2020.00600","volume":"10","author":"PM Hau","year":"2020","unstructured":"Hau, P. M. et al. Targeting Epstein\u2012Barr virus in nasopharyngeal carcinoma. Front. Oncol. 10, 600 (2020).","journal-title":"Front. Oncol."},{"key":"2645_CR7","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai, H. Q. et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat. Med. 27, 1536\u20131543 (2021).","journal-title":"Nat. Med."},{"key":"2645_CR8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai, H. Q. et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 330, 1961\u20131970 (2023).","journal-title":"JAMA"},{"key":"2645_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicenter, randomized, double-blind, phase 3 trial. Lancet Oncol. 22, 1162\u20131174 (2021).","journal-title":"Lancet Oncol."},{"key":"2645_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41, 1061\u20131072 (2023).","journal-title":"Cancer Cell"},{"key":"2645_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","volume":"34","author":"P Bossi","year":"2023","unstructured":"Bossi, P., Chan, A. T., Even, C. & Machiels, J. P. ESMO-EURACAN clinical practice guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease. Ann. Oncol. 34, 247\u2013250 (2023).","journal-title":"Ann. Oncol."},{"key":"2645_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang, T. et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol. Immun. 67, 1079\u20131090 (2018).","journal-title":"Cancer Immunol. Immun."},{"key":"2645_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/19420862.2015.1022692","volume":"7","author":"M Kinder","year":"2015","unstructured":"Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E. & Brezski, R. J. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs 7, 494\u2013504 (2015).","journal-title":"MAbs"},{"key":"2645_CR14","doi-asserted-by":"publisher","first-page":"924542","DOI":"10.3389\/fimmu.2022.924542","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang, Z. et al. Penpulimab, an Fc-engineered IgG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events. Front. Immunol. 13, 924542 (2022).","journal-title":"Front. Immunol."},{"key":"2645_CR15","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Penpulimab: first approval. Drugs 81, 2159\u20132166 (2021).","journal-title":"Drugs"},{"key":"2645_CR16","doi-asserted-by":"publisher","first-page":"684867","DOI":"10.3389\/fonc.2021.684867","volume":"11","author":"C Han","year":"2021","unstructured":"Han, C. et al. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, Phase Ib\/II Trial (AK105-203). Front. Oncol. 11, 684867 (2021).","journal-title":"Front. Oncol."},{"key":"2645_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan, R. et al. Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28, 285\u2013295 (2015).","journal-title":"Cancer Cell"},{"key":"2645_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","volume":"12","author":"H Zhong","year":"2024","unstructured":"Zhong, H. et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small cell lung cancer in China (AK105-302): a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir. Med. 12, 355\u2013365 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2645_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41392-024-01865-6","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal Transduct. Target Ther. 9, 148 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2645_CR20","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1002\/lary.28983","volume":"131","author":"Y Xu","year":"2021","unstructured":"Xu, Y., Huang, T., Mao, M., Zhai, J. & Chen, J. Metastatic patterns and prognosis of de novo metastatic nasopharyngeal carcinoma in the United States. Laryngoscope 131, E1130\u2013E1138 (2021).","journal-title":"Laryngoscope"},{"key":"2645_CR21","doi-asserted-by":"publisher","first-page":"105200","DOI":"10.1016\/j.oraloncology.2021.105200","volume":"115","author":"M Lin","year":"2021","unstructured":"Lin, M. et al. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in nonepidemic areas. Oral Oncol. 115, 105200 (2021).","journal-title":"Oral Oncol."},{"key":"2645_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang, F. H. et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J. Clin. Oncol. 39, 704\u2013712 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2645_CR23","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/ijc.32380","volume":"145","author":"R You","year":"2019","unstructured":"You, R. et al. Relationship of circulating tumor cells and Epstein\u2012Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int. J. Cancer. 145, 2873\u20132883 (2019).","journal-title":"Int. J. Cancer."},{"key":"2645_CR24","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","volume":"36","author":"ATC Chan","year":"2018","unstructured":"Chan, A. T. C. et al. Analysis of plasma Epstein\u2012Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J. Clin. Oncol. 36, 3091\u20133100 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02645-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:01:42Z","timestamp":1775606502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02645-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2645"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02645-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.Y., D.L., M.H., Z.M.W., B.L., and M.X. are employees of Akeso Biopharma. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}